X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.yicaiglobal.com/news/fruquintinib-becomes-first-shanghai-made-antineoplastic-drug-to-be-prescribed-in-us
https://www.globenewswire.com/news-release/2020/09/20/2096198/0/en/Chi-Med-Highlights-Surufatinib-Phase-III-Results-in-Neuroendocrine-Tumors-at-ESMO-2020-and-Publications-in-The-Lancet-Oncology.html
https://www.globenewswire.com/news-release/2020/09/04/2088898/0/en/Chi-Med-Initiates-FRESCO-2-a-Global-Phase-III-Trial-of-Fruquintinib-in-Metastatic-Colorectal-Cancer.html
https://www.globenewswire.com/news-release/2020/05/26/2038329/0/en/Chi-Med-and-BeiGene-Enter-into-Clinical-Collaboration-to-Evaluate-Combinations-of-Surufatinib-and-Fruquintinib-with-Tislelizumab.html
https://www.biospace.com/article/releases/chi-med-announces-that-surufatinib-phase-iii-sanet-p-study-has-already-achieved-its-primary-endpoint-in-advanced-pancreatic-neuroendocrine-tumors-in-china-and-will-stop-early/
https://www.chi-med.com/surufatinib-in-non-pancreatic-net-granted-priority-review-in-china/
https://www.biospace.com/article/releases/chi-med-announces-surufatinib-granted-fda-orphan-drug-designation-for-pancreatic-neuroendocrine-tumors/?s=62
https://www.biospace.com/article/releases/chi-med-highlights-publication-of-phase-ii-data-showing-promising-efficacy-for-savolitinib-in-met-amplified-gastric-cancers/?s=95
Market Place
Share 
